Fake Blood Cancer Medicines Alert: DRAP Warns Pakistan
The Drug Regulatory Authority of Pakistan (DRAP) has issued a nationwide warning after the World Health Organization reported Fake Cancer Medicines in international markets. The alert covers counterfeit blood cancer medicines that could put patients at serious risk. Therefore, DRAP has ordered an immediate ban on the affected batches across Pakistan.
According to DRAP, the counterfeit products include Darzalex injections and Jakavi tablets. These medicines are commonly used to treat different types of blood cancer. Officials identified fake batches of Darzalex 400 mg and 100 mg injections. In addition, they found counterfeit batches of Jakavi 15 mg and 10 mg tablets.
WHO Identifies Counterfeit Batches
The World Health Organization reported that falsified Darzalex batches appeared in the Maldives and Mexico. Meanwhile, counterfeit Jakavi packaging displayed the address of Novartis Pharma Switzerland. DRAP also noted that fake Darzalex packs carried the address of Janssen-Cilag Belgium. However, the medicines were not genuine products from the manufacturers.
Health officials explained that laboratory checks raised serious concerns. They could not verify the raw materials used in the samples. Moreover, one Darzalex sample contained foreign particles. As a result, experts warned that these medicines may not work as intended and could seriously harm patients.
DRAP Orders Immediate Ban
DRAP has banned the sale, distribution, and use of all affected batches. Furthermore, the regulator urged hospitals, pharmacies, and healthcare professionals to avoid these products. Patients should also check medicines carefully and seek advice from qualified healthcare providers before use.
Public Asked to Stay Alert
The authority said it will continue monitoring the pharmaceutical market for counterfeit products. It also promised strict action against anyone involved in supplying falsified medicines. Meanwhile, DRAP encouraged the public to report suspicious medicines through official channels. These steps aim to protect patients and strengthen confidence in Pakistan’s medicine supply system
